DIA wants you to continue to benefit from opportunities to learn and grow professionally, year-round.

DIA’s Annual Meeting Comes Once a Year. Were You There? If you missed this year’s DIA Annual Meeting, you can now purchase content that was delivered at this year’s program! DIA wants you to continue to benefit from opportunities to learn and grow professionally, year-round.      • View available presentations for 280 + educational offerings        captured in digital audio with synchronized slides      • Download available offerings in MP3 format to your mobile        device for portable listening      • Check out the DIA 2012 Annual Meeting final program and see        all the special topics that were covered The DIA 2012 48th Annual Meeting includes a comprehensive coverage of today's hottest topics, such as PDUFA V, biosimilars, tailored therapies, personalized medicine, social media, region-specific content, and much more! Entire Meeting Package: $799.99 Individual Session Price: $59.99 Track Price: $199 - $299 Read issues of the DIA 2012 48th Annual Meeting "Show Daily" Weekend issue Monday's issue Tuesday's issue Wednesday's issue DIA 2013 49th Annual Meeting Call for Abstracts Now Open! DIA 2013 49th Annual Meeting “Advancing Therapeutic Innovation and Regulatory Science” June 23-27, 2013 Boston, MA Submission Deadline: COB, September 12 Abstract Guidelines Submit Abstract Online See What You Missed at DIA 2012 48th Annual Meeting in Philadelphia… Hear FDA's Margaret Hamburg discuss how three of the most influential regulatory agencies--FDA, EMA, and Health Canada--can collaborate to harmonize technical requirements under the ICH; establish confidentiality arrangements; collaborate on inspection pilots; exchange working level scientific and regulatory policies, procedures, and reports; and implement technical level "clusters" of agency reviewers. Read a complete session follow-up. Questions? For questions related to the content of the Annual Meeting program, email the Annual Meeting Team. Technical Difficulties? If you experience technical difficulties while purchasing, please contact multiviewmediasupport@multiview.com or call 289-695-5400. Note: Continuing education credits are NOT available for archived content accessed through the Live Learning Center. Content available for 18 months and will expire on December 28, 2013.

Physician Payments Sunshine Act is part of the Patient Protection and Affordable Care Act - from Philly Pharma's David Sell

The Physician Payments Sunshine Act is part of the Patient Protection and Affordable Care Act, all of which hangs in the balance Thursday morning when the U.S. Supreme Court will likely rule on the constitutionality of all or parts of the package.

One legal possibility is that the court could decide to defer a decision until the law is fully implemented in 2014, but the betting line has the nine justices making history, one way or another. And, yes, there is a betting line.

The Sunshine Act requires pharmaceutical and medical device companies to report payments made to doctors and teaching hospitals. It is designed to give patients and others more information and shed light on potential conflicts of interest. The question is whether a doctor paid by a company is more inclined to prescribe that company's drug over a competitor's drug or no drug because of his or her financial relationship with the first company, regardless of the effect on the patient.

The Sunshine Act was the topic of a panel discussion Wednesday afternoon at the Drug Information Association's 48th annual meeting at the Philadelphia Convention Center. The meeting concludes Thursday morning.

Read more: http://www.philly.com/philly/blogs/phillypharma/160627445.html#ixzz1zBXhqbbg
Watch sports videos you won't find anywhere else

Supreme Court Ruling Generates Widespread Reaction During the DIA 2012 48th Annual Meeting

For Immediate Release Supreme Court Ruling Generates Widespread Reaction During the DIA 2012 48th Annual Meeting JUNE 28, 2012—HORSHAM, PA—The Supreme Court today voted 5-4 to uphold President Obama’s Affordable Care Act, affirming the centerpiece of the sweeping 2010 overhaul of the nation’s medical industries. “Today’s Supreme Court decision will impact patient access to medical products and treatments,” explains Paul Pomerantz, DIA Worldwide Executive Director.”It also provides clarity and direction to allow DIA to continue to create forums to exchange vital information and discuss current issues to ensure patient access to safe, effective, and affordable medical products.” In his decision, Chief Justice John Roberts explained that the individual mandate survives because Congress has the power to impose taxes. Today’s announcement came during the DIA 2012 Annual Meeting CDER Town Hall—generating mixed reaction from the 600 people in attendance. "It sure seems like the right thing to do," says Patrick Revelle, MedDRA MSSO. "It seems an odd position for someone to be against. I have health care coverage, but many other people don't." Greg Gogates of CRF Health noted that the Supreme Court considers the individ¬ual mandate to be tax on those who do not have health insurance. "I understand the concept,” he says. “But where are the people who already have no money for health insurance going to come up with the money to pay for this tax?" Starting in 2014, the Affordable Care Act will extend health insurance to approximately 30 million Americans who currently lack coverage. It will also guarantee the availability of insurance for those with pre-existing conditions and ensure those people don’t pay more than healthy people. Anyone earning up to 133% of the federal poverty level will get free coverage through Medicaid and those earning 133% to 400% (but without access to employer or government insurance) will be eligible for federal subsidies to help them buy policies. As a frequent visitor to the US, and also having lived here for a couple years, Thomas Kuhler of Novo Nordisk A/S, Denmark congratulated the Supreme Court’s decision noting, "This [decision] represents a great step forward." Contact: Joe Krasowski DIA Marketing Communications Manager P: 215-293-5812 E: Joe.Krasowski@diahome.org

#DIA2012 - Highlights for Wednesday, June 27

#DIA2012 - Tuesday, June 26 Highlights

 

Global Regulatory Sessions at #DIA2012 - still to come on Wednesday and Thursday!

DIA 2012 Annual Meeting is chock-full of global gatherings just for you! Sessions for regions such as Europe and Latin America, and country- specific sessions on Japan, China, India as well as tracks on rare diseases. Network, listen, and learn with your global counterparts. Don’t miss the most well-rounded special global sessions you’ll find in one place, at one time, anywhere! THANK YOU TO  OUR DIA LEVEL 2 SUPPORTER THANK YOU TO OUR DIA LEVEL 1 SUPPORTERS                Follow DIA DIA’s Global Sessions are created for countries who are going through regulatory changes, drug developments and policy challenges, and are searching for innovative solutions just like you. Wednesday, June 27 Natural History Studies for Rare Diseases and Orphan Conditions Overview of the history and future of rare diseases. Partnering for Impact in Global Health Join professionals from the Bill & Melinda Gates Foundation to confer on the Foundation’s “Decade of Vaccines” effort.  CBER Town Hall Get updated on CBER’s latest guidances and initiatives. Orphan Drug Development: Global Regulatory Challenges and Initiatives Discussing the crucial need for developing orphans drugs. Pharmaceuticals and Medical Devices Agency (PMDA) Town Hall In addition to answering pertinent questions, PMDA will explain its current services and the Japanese drug regulation. India Regulatory Town Hall Regulatory authorities of India will provide information on initiatives, guidances, and regulations. Thursday, June 28 CDER Town Hall: Part 1 and Part 2 Discussions on topics of current importance within the CDER communities. Questions? Submit questions in advance.    Online registration is no longer available. Onsite Registration is available for the full conference or one-day!